Sonal Singh1, Yoon K Loke. 1. Wake Forest University School of Medicine, Department of Medicine, Winston-Salem, NC 27103, USA. sosingh@wfubmc.edu
Abstract
BACKGROUND: Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease. OBJECTIVES: To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone. METHODS: Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers. CONCLUSION: Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.
BACKGROUND:Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease. OBJECTIVES: To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone. METHODS: Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers. CONCLUSION:Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.
Authors: Zhouji Chen; Patrick A Vigueira; Kari T Chambers; Angela M Hall; Mayurranjan S Mitra; Nathan Qi; William G McDonald; Jerry R Colca; Rolf F Kletzien; Brian N Finck Journal: J Biol Chem Date: 2012-05-23 Impact factor: 5.157
Authors: Richard G Bach; Maria Mori Brooks; Manuel Lombardero; Saul Genuth; Thomas W Donner; Alan Garber; Laurence Kennedy; E Scott Monrad; Rodica Pop-Busui; Sheryl F Kelsey; Robert L Frye Journal: Circulation Date: 2013-07-15 Impact factor: 29.690